Dupont Capital Management Corp Aurinia Pharmaceuticals Inc. Transaction History

Dupont Capital Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	SELL	$4.11 - $8.14 $65,644 - $130,012	-15,972 Reduced 73.6%	5,730 $0
Q3 2022 Oct 31, 2022	BUY	$6.66 - $12.39 $85,627 - $159,298	12,857 Added 145.36%	21,702 $163,000
Q1 2022 Apr 27, 2022	BUY	$10.05 - $22.48 $2,341 - $5,237	233 Added 2.71%	8,845 $110,000
Q4 2021 Jan 31, 2022	SELL	$17.78 - $33.08 $85,077 - $158,287	-4,785 Reduced 35.72%	8,612 $197,000
Q3 2021 Nov 03, 2021	BUY	$10.93 - $23.55 $146,429 - $315,499	13,397 New	13,397 $296,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.